Yunlu Xue

Yunlu Xue

Auto-generated profile, based on publicly available information

Yunlu Xue

Departments of Genetics and Ophthalmology, Blavatnik Institute, Harvard Medical School

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
WXWenjun XIONG
Wenjun XIONG
DWDavid M. Wu
David M. Wu
YXYunlu Xue
Yunlu Xue
SWSean K. Wang
Sean K. Wang
MCMichelle J. Chung
Michelle J. Chung
CCConstance L. Cepko
Constance L. Cepko
Adeno-associated viral vectors (AAVs) have become popular for gene therapy, given their many advantages, including their reduced inflammatory profile compared with that of other viruses. However, even in areas of immune privilege such as the eye, AAV vectors are capable of eliciting host-cell responses. To investigate the effects of such responses on several ocular cell types, we tested multiple AAV genome structures and capsid types using subretinal injections in mice. Assays of morphology, inflammation, and physiology were performed. Pathological effects on photoreceptors and the retinal pigment epithelium (RPE) were observed. Müller glia and microglia were activated, and the proinflammatory cytokines TNF-α and IL-1β were up-regulated. There was a strong correlation between cis-regulatory sequences and toxicity. AAVs with any one of three broadly active promoters, or an RPE-specific promoter, were toxic, while AAVs with four different photoreceptor-specific promoters were not toxic at the highest doses tested. There was little correlation between toxicity and transgene, capsid type, preparation method, or cellular contaminants within a preparation. The toxic effect was dose-dependent, with the RPE being more sensitive than photoreceptors. Our results suggest that ocular AAV toxicity is associated with certain AAV cis-regulatory sequences and/or their activity and that retinal damage occurs due to responses by the RPE and/or microglia. By applying multiple, sensitive assays of toxicity, AAV vectors can be designed so that they can be used safely at high dose, potentially providing greater therapeutic efficacy. Significance Adeno-associated viral (AAV) gene therapy is becoming an important therapeutic modality, especially for ocular diseases, due to its efficiency of gene delivery and relative lack of pathogenicity. However, AAV sometimes can cause inflammation and toxicity. We explored such effects using injections into the mouse eye. We found a strong correlation of toxicity and inflammation with the use of promoters that were broadly active, or specifically active in the retinal pigment epithelium. AAVs with photoreceptor-specific promoters were found to be nontoxic at all doses tested. These studies reveal that safer vectors can be designed if assays for relevant and specific cell types are developed and tested with a range of vectors with different genomic elements.

10 February 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
YCYing Kai Chan
Ying Kai Chan
SWSean K. Wang
Sean K. Wang
CCColin J. Chu
Colin J. Chu
DCDavid A. Copland
David A. Copland
ALAlexander J. Letizia
Alexander J. Letizia
GCGeorge Church
George Church
Incorporating TLR9-inhibitory sequences in the AAV vector genome inhibits immunogenicity and enhances transgene expression in multiple animal models.

20 January 2015 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YXYunlu Xue
Yunlu Xue
SSSusan Q. Shen
Susan Q. Shen
JJJonathan Jui
Jonathan Jui
ARAlan C. Rupp
Alan C. Rupp
LBLeah C. Byrne
Leah C. Byrne
VKVladimir J. Kefalov
Vladimir J. Kefalov
Mutations in the cellular retinaldehyde–binding protein (CRALBP, encoded by RLBP1) can lead to severe cone photoreceptor–mediated vision loss in patients. It is not known how CRALBP supports cone function or how altered CRALBP leads to cone dysfunction. Here, we determined that deletion of Rlbp1 in mice impairs the retinal visual cycle. Mice lacking CRALBP exhibited M-opsin mislocalization, M-cone loss, and impaired cone-driven visual behavior and light responses. Additionally, M-cone dark adaptation was largely suppressed in CRALBP-deficient animals. While rearing CRALBP-deficient mice in the dark prevented the deterioration of cone function, it did not rescue cone dark adaptation. Adeno-associated virus–mediated restoration of CRALBP expression specifically in Müller cells, but not retinal pigment epithelial (RPE) cells, rescued the retinal visual cycle and M-cone sensitivity in knockout mice. Our results identify Müller cell CRALBP as a key component of the retinal visual cycle and demonstrate that this pathway is important for maintaining normal cone–driven vision and accelerating cone dark adaptation.

25 January 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
DWDavid Wu
David Wu
XJXuke Ji
Xuke Ji
MIMaryna Ivanchenko
Maryna Ivanchenko
MCMichelle Chung
Michelle Chung
MPMary Piper
Mary Piper
CCConstance L. Cepko
Constance L. Cepko
Nrf2, a transcription factor that regulates the response to oxidative stress, has been shown to rescue cone photoreceptors and slow vision loss in mouse models of retinal degeneration (rd). The retinal pigment epithelium (RPE) is damaged in these models, but whether it also could be rescued by Nrf2 has not been previously examined. We used an adeno-associated virus (AAV) with an RPE-specific (Best1) promoter to overexpress Nrf2 in the RPE of rd mice. Control rd mice showed disruption of the regular array of the RPE, as well as loss of RPE cells. Cones were lost in circumscribed regions within the cone photoreceptor layer. Overexpression of Nrf2 specifically in the RPE was sufficient to rescue the RPE, as well as the disruptions in the cone photoreceptor layer. Electron microscopy showed compromised apical microvilli in control rd mice but showed preserved microvilli in Best1-Nrf2–treated mice. The rd mice treated with Best1-Nrf2 had slightly better visual acuity. Transcriptome profiling showed that Nrf2 upregulates multiple oxidative defense pathways, reversing declines seen in the glutathione pathway in control rd mice. In summary, Nrf2 overexpression in the RPE preserves RPE morphology and survival in rd mice, and it is a potential therapeutic for diseases involving RPE degeneration, including age-related macular degeneration (AMD).

3 August 2020 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SWSean K. Wang
Sean K. Wang
YXYunlu Xue
Yunlu Xue
CCConstance L. Cepko
Constance L. Cepko
Retinitis pigmentosa (RP) is a genetically heterogenous group of eye diseases in which initial degeneration of rods triggers secondary degeneration of cones, leading to significant loss of daylight, color, and high-acuity vision. Gene complementation with adeno-associated viral (AAV) vectors is one strategy to treat RP. Its implementation faces substantial challenges, however; for example, the tremendous number of loci with causal mutations. Gene therapy targeting secondary cone degeneration is an alternative approach that could provide a much-needed generic treatment for many patients with RP. Here, we show that microglia are required for the upregulation of potentially neurotoxic inflammatory factors during cone degeneration in RP, creating conditions that might contribute to cone dysfunction and death. To ameliorate the effects of such factors, we used AAV vectors to express isoforms of the antiinflammatory cytokine transforming growth factor beta (TGF-β). AAV-mediated delivery of TGF-β1 rescued degenerating cones in 3 mouse models of RP carrying different pathogenic mutations. Treatment with TGF-β1 protected vision, as measured by 2 behavioral assays, and could be pharmacologically disrupted by either depleting microglia or blocking the TGF-β receptors. Our results suggest that TGF-β1 may be broadly beneficial for patients with cone degeneration, and potentially other forms of neurodegeneration, through a pathway dependent upon microglia.

29 April 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SWSean K. Wang
Sean K. Wang
YXYunlu Xue
Yunlu Xue
PRParimal Rana
Parimal Rana
CHChristin M. Hong
Christin M. Hong
CCConstance L. Cepko
Constance L. Cepko
Significance: Retinitis pigmentosa (RP) is a genetically heterogenous disease that lacks effective treatment. In RP, there is degeneration of cone photoreceptors in the eye, often leading to complete blindness. The reasons for cone degeneration remain largely unknown. Development of therapies that preserve cones and vision in patients with RP, particularly in a mutation-independent manner, would benefit from a greater understanding of the underlying pathological mechanisms. We examined immune responses in RP mice during the period of cone degeneration and identified soluble CX3CL1 (sCX3CL1) as a promising therapy for cones. Viral-mediated expression of sCX3CL1 prolonged cone survival in different RP models and improved visual function. These results establish viral delivery of sCX3CL1 as a potential treatment for RP and other retinal disorders.